Lareau helps detect more infectious COVID variant at Berkeley

COVID evolutionary tree

Professor Liana Lareau has been co-leading the Innovative Genomics Institute effort to monitor mutations in the SARS-CoV-2 virus in the local community. The team’s rapid sequencing turnaround is crucial for tracking the spread of new variants, including the more infectious B.1.1.7 recently detected in two cases at Berkeley.

Read More

New CRISPR-based COVID-19 test uses smartphone cameras to spot virus RNA

photo of smartphone CRISPR covid test apparatus

Fletcher Lab, in collaboration with the Gladstone Institutes and Doudna Lab, have developed a new CRISPR-based COVID-19 diagnostic test that, with the help of a smartphone camera, can provide a positive or negative result in 15 to 30 minutes. This test also gives an estimate of viral load, or the number of virus particles in a sample, which can help doctors monitor the progression of a COVID-19 infection and estimate how contagious a patient might be.

Read More

FDA authorizes first rapid at-home covid-19 test, made by Lucira

Lucira covid test packaging

On Tuesday the first rapid, at-home COVID-19 test was authorized by the Food and Drug Administration. The test, made by BioE-founded company Lucira, uses their loop mediated amplification reaction process, a molecular nucleic acid amplification technology, in a battery-powered standalone unit. Rather than detecting antibodies, their test is designed to detect whether an individual is shedding the coronavirus that causes COVID-19. The company was developing this technology for an at-home influenza test before rapidly pivoting to address COVID-19. Lucira is led by Debkishore Mitra (PhD 2013), who founded the company with John Waldeisen (PhD 2012).

Read More

Lareau receives LGR Seed Funding award for COVID-19 Project

lareau

Prof Liana Lareau and collaborator Stacia Wyman have received one of ten Excellence in Research Awards from the Laboratory for Genomics Research (LGR), a collaboration between UC Berkeley/UCSF (IGI) and GlaxoSmithKline. Their project will explore rapid, low-cost, high-throughput viral and metagenome sequencing of COVID-19 patient samples for outbreak surveillance.

Read More

Head-Gordon leads COVID-19 Drug-Delivery Simulation Repository

coronavirus computer graphic

The Molecular Sciences Software Institute (MolSSI) has launched an open-source website that will allow biomolecular scientists from around the world to share computer-aided drug-testing simulations targeting the protein at the center of COVID-19. Under the leadership of MolSSI co-director Teresa Head-Gordon, a MolSSI team started work on the COVID-19 website in April, after scores of scientists began discussing ways to share simulation modeling data they had on the coronavirus.

Read More